Disclaimer: CJC-1295 without DAC is sold strictly for laboratory research purposes only. It is not approved for human consumption or medical use. This article discusses published scientific research and does not constitute medical advice or treatment recommendations.
Understanding CJC-1295 Without DAC
CJC-1295 without DAC, also known as Modified GRF(1-29) or Mod GRF 1-29, is a synthetic analogue of growth hormone releasing hormone (GHRH). The peptide consists of the first 29 amino acids of GHRH with four amino acid substitutions designed to enhance stability against enzymatic degradation.
The “without DAC” designation refers to the absence of Drug Affinity Complex, a modification that extends half-life through albumin binding. CJC-1295 without DAC maintains a shorter half-life (approximately 30 minutes), creating pulsatile growth hormone (GH) release that more closely mimics physiological secretion patterns compared to the DAC version. Early research by Jetté et al. identified CJC-1295 as a stable GHRH(1-29) analog with extended plasma persistence, demonstrating a 4-fold increase in GH area under the curve compared to native hGRF(1-29) in animal models (PMID: 15817669).
Mechanism of Action
CJC-1295 without DAC stimulates GH release through several well-characterized mechanisms. This compound is intended for laboratory research use only and is not approved for human consumption.
GHRH Receptor Activation: Modified GRF(1-29) binds to GHRH receptors on pituitary somatotrophs with similar affinity to native GHRH, activating adenylyl cyclase and increasing intracellular cAMP levels. This mechanism was demonstrated in foundational receptor-binding studies and confirmed in clinical pharmacology trials (Teichman et al., 2006).
Enhanced Stability: The four amino acid substitutions (positions 2, 8, 15, and 27) confer significant resistance to dipeptidyl peptidase-4 (DPP-4) degradation while maintaining GHRH receptor binding affinity, addressing the primary limitation of native GHRH’s extremely short plasma half-life.
Pulsatile GH Release: A pivotal investigation by Ionescu and Frohman demonstrated that pulsatile GH secretion persists during continuous CJC-1295 stimulation, with overall GH secretion increasing by 46% and basal (trough) GH levels increasing 7.5-fold, while the frequency and magnitude of GH secretory pulses remained unaltered (PMID: 17018654).
Synergy with GHRPs: The well-documented synergistic effect when GHRH analogues are combined with growth hormone releasing peptides (GHRPs) produces GH release exceeding the sum of individual effects. This synergy is attributed to GHRH working through the cAMP pathway while GHRPs signal through calcium/protein kinase C pathways via the ghrelin receptor (GHS-R1a). Raun et al. characterized ipamorelin as the first selective GHRP-receptor agonist, noting it stimulates GH release without affecting ACTH or cortisol — making it a particularly favorable combination partner (PMID: 9849822).
Growth Hormone and IGF-1 Research
Studies have characterized CJC-1295 without DAC’s effects on the GH/IGF-1 axis with considerable detail:
The landmark pharmacokinetic study by Teichman et al. (2006) published in the Journal of Clinical Endocrinology & Metabolism examined CJC-1295 in healthy adults using a randomized, placebo-controlled, double-blind ascending dose design. A single injection produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more, and IGF-I concentrations increased 1.5- to 3-fold for 9-11 days. After multiple doses, mean IGF-I levels remained above baseline for up to 28 days. The estimated half-life was 5.8–8.1 days, and no serious adverse events were reported (PMID: 16352683).
In a complementary study, Ionescu and Frohman confirmed that CJC-1295 increased both trough and mean GH secretion while preserving the natural pulsatile GH pattern, with IGF-I production rising by 45%. Notably, both 60 and 90 μg/kg doses produced comparable results (PMID: 17018654).
Alba et al. further demonstrated the efficacy of CJC-1295 in GHRH knockout mice, showing that once-daily administration normalized body weight, length, and bone development while stimulating pituitary GH mRNA production (PMID: 16822960).
Body Composition Research
Several studies have examined metabolic and body composition effects of GHRH analogues and growth hormone secretagogues:
Sinha et al. (2020) published a review in Translational Andrology and Urology examining growth hormone secretagogues including sermorelin, GHRP-2, GHRP-6, ibutamoren, and ipamorelin for body composition management. The authors found these compounds function as potent GH and IGF-1 stimulators that can improve body composition, though they concluded that additional longitudinal studies are needed (PMID: 32257855).
Stanley et al. (2011) investigated a GHRH analog (tesamorelin) administered once daily for two weeks in healthy men, finding that the treatment augmented both basal and pulsatile GH secretion with significantly increased IGF-I concentrations, while peripheral insulin-stimulated glucose uptake was not significantly affected — suggesting preserved insulin sensitivity despite elevated GH and IGF-I levels (PMID: 20943777).
All products mentioned are sold for laboratory research purposes only. Not for human or animal consumption.
Sleep and Recovery Research
Growth hormone secretion is closely linked to sleep architecture, particularly slow-wave sleep (SWS). The most reproducible and often the largest GH pulse occurs during early sleep in temporal association with the first phase of deep SWS. GHRH has been identified as the primary factor controlling sleep-associated GH release in both rodent and human studies.
Sigalos and Pastuszak (2018) reviewed the safety and efficacy of growth hormone secretagogues, noting that these compounds may enhance sleep quality in addition to their effects on growth velocity, appetite, lean mass, and bone turnover. The review found GH secretagogues to be generally well tolerated, though it highlighted the need for further long-term safety data (PMID: 28400207).
Dosage in Research Studies
Published research protocols show considerable variation in dosing approaches:
Human studies: Typical doses range from 100–200 mcg per injection (approximately 1–2 mcg/kg)
Frequency: Research examining chronic effects typically uses 1–3 doses daily
Timing: Common protocols dose before breakfast, post-workout, and/or before bed to align with natural GH pulse timing
Combination use: Many studies combine with GHRPs (e.g., ipamorelin, GHRP-2) at 100–200 mcg to leverage synergistic effects
Note: These are research protocols only. CJC-1295 without DAC is not approved for human use outside of research settings.
Safety Considerations in Research
Available safety data comes from both preclinical and clinical studies:
The Teichman et al. (2006) clinical trial reported that CJC-1295 was safe and relatively well tolerated in healthy adults, with no serious adverse events at doses of 30 or 60 μg/kg. Side effects were generally limited to mild injection site reactions (PMID: 16352683).
Sigalos and Pastuszak’s review of growth hormone secretagogue safety noted that GH secretagogues are generally well tolerated, though some concern exists regarding increases in blood glucose due to decreases in insulin sensitivity. The authors emphasized that further work is needed to understand long-term impact, including evaluation of cancer incidence and mortality (PMID: 28400207).
Stanley et al. provided reassuring data showing that a GHRH analog preserved peripheral insulin sensitivity despite significantly elevating GH and IGF-I levels in short-term treatment, though the authors recommended careful monitoring of glucose metabolism in longer protocols (PMID: 20943777).
Unlike CJC-1295 with DAC, concerns about sustained GH elevation and potential negative feedback on natural secretion are reduced with the without-DAC version, as the short half-life and pulsatile nature of Modified GRF(1-29) may minimize hypothalamic-pituitary suppression compared to longer-acting analogues.
Optimal dosing frequencies to best mimic physiological GH pulsatility
Long-term safety and efficacy in various populations
Combination protocols with different GHRPs for specific outcomes
Potential applications in age-related GH decline
Effects on tissue healing and regeneration
Neuroprotective properties and cognitive effects
Comparison with other GHRH analogues (tesamorelin, sermorelin)
Related Research Peptides
Scientists investigating GH secretion also study several related compounds:
Ipamorelin: A selective GHRP often combined with Modified GRF(1-29) for synergistic GH release
CJC-1295 with DAC: The longer-acting version producing sustained rather than pulsatile GH elevation
Tesamorelin: Another GHRH analogue approved for HIV-associated lipodystrophy
Sermorelin: A shorter GHRH analogue (GRF 1-29) without the stability modifications
Conclusion
CJC-1295 without DAC represents an important research tool for investigating physiological GH secretion patterns and the effects of GHRH receptor activation. Its design — incorporating stability modifications while maintaining a short half-life — allows for pulsatile GH release that more closely mimics natural secretion compared to longer-acting analogues.
Clinical research has demonstrated that the peptide effectively stimulates GH pulses with dose-dependent increases in both GH and IGF-1 levels, while preserving the natural pulsatile secretion pattern. The synergistic effects when combined with GHRPs have been well-documented, making combination protocols common in research settings.
However, significant gaps remain in understanding long-term safety, optimal dosing strategies, and the clinical significance of different pulsatile versus sustained GH elevation patterns. Future research will need to address these questions through rigorous, large-scale studies with comprehensive safety monitoring.
CJC-1295 without DAC is supplied for laboratory research purposes only. It is not intended for human or animal consumption and should only be handled by qualified researchers in appropriate research settings.
Research References:
Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab, 91(3):799-805. PubMed
Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab, 91(12):4792-7. PubMed
Jetté L et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7):3052-8. PubMed
Alba M et al. (2006). Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab, 291(6):E1290-4. PubMed
Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 139(5):552-61. PubMed
Stanley TL et al. (2011). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab, 96(1):150-8. PubMed
Sigalos JT, Pastuszak AW (2018). The safety and efficacy of growth hormone secretagogues. Sex Med Rev, 6(1):45-53. PubMed
Sinha DK et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in body composition management. Transl Androl Urol, 9(Suppl 2):S149-S159. PubMed
All research chemicals sold are intended for laboratory research use only. Not for human consumption.
If you’re wondering whether you can legally sell peptides for human consumption, the answer isn’t as simple as yes or no. The legal landscape around peptides is complex and depends on several factors. Let’s break down what’s actually legal and what could land you in hot water. Understanding the Legal Framework for Selling Peptides The …
TB-500 is a synthetic fragment of thymosin beta-4, one of the most studied peptides in regenerative biology. This article reviews the peer-reviewed research behind its mechanisms, from actin sequestration to anti-fibrotic signaling, across cardiac, ocular, neurological, and tissue repair applications.
Curious about the buzz around KPV peptide benefits? This powerful alpha-msh-fragment is making waves for its impressive anti-inflammatory effects, and researchers are excited about its potential for healing the gut, soothing the skin, and boosting immunity more gently than GLP1-S.
CJC-1295 Without DAC: Research on Modified Growth Hormone Releasing Hormone
Disclaimer: CJC-1295 without DAC is sold strictly for laboratory research purposes only. It is not approved for human consumption or medical use. This article discusses published scientific research and does not constitute medical advice or treatment recommendations.
Understanding CJC-1295 Without DAC
CJC-1295 without DAC, also known as Modified GRF(1-29) or Mod GRF 1-29, is a synthetic analogue of growth hormone releasing hormone (GHRH). The peptide consists of the first 29 amino acids of GHRH with four amino acid substitutions designed to enhance stability against enzymatic degradation.
The “without DAC” designation refers to the absence of Drug Affinity Complex, a modification that extends half-life through albumin binding. CJC-1295 without DAC maintains a shorter half-life (approximately 30 minutes), creating pulsatile growth hormone (GH) release that more closely mimics physiological secretion patterns compared to the DAC version. Early research by Jetté et al. identified CJC-1295 as a stable GHRH(1-29) analog with extended plasma persistence, demonstrating a 4-fold increase in GH area under the curve compared to native hGRF(1-29) in animal models (PMID: 15817669).
Mechanism of Action
CJC-1295 without DAC stimulates GH release through several well-characterized mechanisms. This compound is intended for laboratory research use only and is not approved for human consumption.
Growth Hormone and IGF-1 Research
Studies have characterized CJC-1295 without DAC’s effects on the GH/IGF-1 axis with considerable detail:
The landmark pharmacokinetic study by Teichman et al. (2006) published in the Journal of Clinical Endocrinology & Metabolism examined CJC-1295 in healthy adults using a randomized, placebo-controlled, double-blind ascending dose design. A single injection produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more, and IGF-I concentrations increased 1.5- to 3-fold for 9-11 days. After multiple doses, mean IGF-I levels remained above baseline for up to 28 days. The estimated half-life was 5.8–8.1 days, and no serious adverse events were reported (PMID: 16352683).
In a complementary study, Ionescu and Frohman confirmed that CJC-1295 increased both trough and mean GH secretion while preserving the natural pulsatile GH pattern, with IGF-I production rising by 45%. Notably, both 60 and 90 μg/kg doses produced comparable results (PMID: 17018654).
Alba et al. further demonstrated the efficacy of CJC-1295 in GHRH knockout mice, showing that once-daily administration normalized body weight, length, and bone development while stimulating pituitary GH mRNA production (PMID: 16822960).
Body Composition Research
Several studies have examined metabolic and body composition effects of GHRH analogues and growth hormone secretagogues:
Sinha et al. (2020) published a review in Translational Andrology and Urology examining growth hormone secretagogues including sermorelin, GHRP-2, GHRP-6, ibutamoren, and ipamorelin for body composition management. The authors found these compounds function as potent GH and IGF-1 stimulators that can improve body composition, though they concluded that additional longitudinal studies are needed (PMID: 32257855).
Stanley et al. (2011) investigated a GHRH analog (tesamorelin) administered once daily for two weeks in healthy men, finding that the treatment augmented both basal and pulsatile GH secretion with significantly increased IGF-I concentrations, while peripheral insulin-stimulated glucose uptake was not significantly affected — suggesting preserved insulin sensitivity despite elevated GH and IGF-I levels (PMID: 20943777).
All products mentioned are sold for laboratory research purposes only. Not for human or animal consumption.
Sleep and Recovery Research
Growth hormone secretion is closely linked to sleep architecture, particularly slow-wave sleep (SWS). The most reproducible and often the largest GH pulse occurs during early sleep in temporal association with the first phase of deep SWS. GHRH has been identified as the primary factor controlling sleep-associated GH release in both rodent and human studies.
Sigalos and Pastuszak (2018) reviewed the safety and efficacy of growth hormone secretagogues, noting that these compounds may enhance sleep quality in addition to their effects on growth velocity, appetite, lean mass, and bone turnover. The review found GH secretagogues to be generally well tolerated, though it highlighted the need for further long-term safety data (PMID: 28400207).
Dosage in Research Studies
Published research protocols show considerable variation in dosing approaches:
Note: These are research protocols only. CJC-1295 without DAC is not approved for human use outside of research settings.
Safety Considerations in Research
Available safety data comes from both preclinical and clinical studies:
The Teichman et al. (2006) clinical trial reported that CJC-1295 was safe and relatively well tolerated in healthy adults, with no serious adverse events at doses of 30 or 60 μg/kg. Side effects were generally limited to mild injection site reactions (PMID: 16352683).
Sigalos and Pastuszak’s review of growth hormone secretagogue safety noted that GH secretagogues are generally well tolerated, though some concern exists regarding increases in blood glucose due to decreases in insulin sensitivity. The authors emphasized that further work is needed to understand long-term impact, including evaluation of cancer incidence and mortality (PMID: 28400207).
Stanley et al. provided reassuring data showing that a GHRH analog preserved peripheral insulin sensitivity despite significantly elevating GH and IGF-I levels in short-term treatment, though the authors recommended careful monitoring of glucose metabolism in longer protocols (PMID: 20943777).
Unlike CJC-1295 with DAC, concerns about sustained GH elevation and potential negative feedback on natural secretion are reduced with the without-DAC version, as the short half-life and pulsatile nature of Modified GRF(1-29) may minimize hypothalamic-pituitary suppression compared to longer-acting analogues.
Current Research Directions
Ongoing investigations are examining:
Related Research Peptides
Scientists investigating GH secretion also study several related compounds:
Conclusion
CJC-1295 without DAC represents an important research tool for investigating physiological GH secretion patterns and the effects of GHRH receptor activation. Its design — incorporating stability modifications while maintaining a short half-life — allows for pulsatile GH release that more closely mimics natural secretion compared to longer-acting analogues.
Clinical research has demonstrated that the peptide effectively stimulates GH pulses with dose-dependent increases in both GH and IGF-1 levels, while preserving the natural pulsatile secretion pattern. The synergistic effects when combined with GHRPs have been well-documented, making combination protocols common in research settings.
However, significant gaps remain in understanding long-term safety, optimal dosing strategies, and the clinical significance of different pulsatile versus sustained GH elevation patterns. Future research will need to address these questions through rigorous, large-scale studies with comprehensive safety monitoring.
CJC-1295 without DAC is supplied for laboratory research purposes only. It is not intended for human or animal consumption and should only be handled by qualified researchers in appropriate research settings.
Research References:
All research chemicals sold are intended for laboratory research use only. Not for human consumption.
Related Posts
Is it Legal to Sell Peptides for Humans?
If you’re wondering whether you can legally sell peptides for human consumption, the answer isn’t as simple as yes or no. The legal landscape around peptides is complex and depends on several factors. Let’s break down what’s actually legal and what could land you in hot water. Understanding the Legal Framework for Selling Peptides The …
What Is TB-500? Understanding Thymosin Beta-4 in Research
TB-500 is a synthetic fragment of thymosin beta-4, one of the most studied peptides in regenerative biology. This article reviews the peer-reviewed research behind its mechanisms, from actin sequestration to anti-fibrotic signaling, across cardiac, ocular, neurological, and tissue repair applications.
KPV Peptide Benefits: Can Alpha-MSH-Fragment Outperform GLP1-S?
Curious about the buzz around KPV peptide benefits? This powerful alpha-msh-fragment is making waves for its impressive anti-inflammatory effects, and researchers are excited about its potential for healing the gut, soothing the skin, and boosting immunity more gently than GLP1-S.